CN109320461B - 一种替米沙坦中间体的制备方法 - Google Patents
一种替米沙坦中间体的制备方法 Download PDFInfo
- Publication number
- CN109320461B CN109320461B CN201811514781.0A CN201811514781A CN109320461B CN 109320461 B CN109320461 B CN 109320461B CN 201811514781 A CN201811514781 A CN 201811514781A CN 109320461 B CN109320461 B CN 109320461B
- Authority
- CN
- China
- Prior art keywords
- methyl
- propyl
- butyronitrile
- solution
- carboxybenzimidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title claims abstract description 30
- 229960005187 telmisartan Drugs 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 33
- XWAJTVCEILFDGU-UHFFFAOYSA-N 7-methyl-2-propyl-3h-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(CCC)=NC2=C1C XWAJTVCEILFDGU-UHFFFAOYSA-N 0.000 claims abstract description 26
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000005708 Sodium hypochlorite Substances 0.000 claims abstract description 16
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims abstract description 16
- NHFKECPTBZZFBC-UHFFFAOYSA-N 4-amino-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1N NHFKECPTBZZFBC-UHFFFAOYSA-N 0.000 claims abstract description 11
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 claims abstract description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 66
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 40
- 238000003756 stirring Methods 0.000 claims description 40
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 239000007789 gas Substances 0.000 claims description 19
- 229960000583 acetic acid Drugs 0.000 claims description 18
- 239000012362 glacial acetic acid Substances 0.000 claims description 14
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 7
- 239000003651 drinking water Substances 0.000 claims description 7
- 235000020188 drinking water Nutrition 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000012295 chemical reaction liquid Substances 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 238000004042 decolorization Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000009776 industrial production Methods 0.000 abstract description 3
- 239000000052 vinegar Substances 0.000 abstract 1
- 235000021419 vinegar Nutrition 0.000 abstract 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 11
- 150000008363 butyronitriles Chemical class 0.000 description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960004050 aminobenzoic acid Drugs 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 101150059573 AGTR1 gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- -1 2-n-propyl-4-methyl-6-carboxyl benzimidazole (mono-imidazole) Chemical compound 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811514781.0A CN109320461B (zh) | 2018-12-12 | 2018-12-12 | 一种替米沙坦中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811514781.0A CN109320461B (zh) | 2018-12-12 | 2018-12-12 | 一种替米沙坦中间体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109320461A CN109320461A (zh) | 2019-02-12 |
CN109320461B true CN109320461B (zh) | 2020-02-07 |
Family
ID=65257227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811514781.0A Active CN109320461B (zh) | 2018-12-12 | 2018-12-12 | 一种替米沙坦中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109320461B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112624979A (zh) * | 2019-10-09 | 2021-04-09 | 浙江瑞博制药有限公司 | 一种苯并咪唑化合物的制备方法 |
CN110713463A (zh) * | 2019-10-25 | 2020-01-21 | 合肥立方制药股份有限公司 | 2-正丙基-4-甲基-6-羧酸苯并咪唑的制备方法 |
CN114163391B (zh) * | 2021-12-14 | 2024-02-02 | 迪嘉药业集团股份有限公司 | 一种坎地沙坦中间体及坎地沙坦的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010149360A1 (en) * | 2009-06-26 | 2010-12-29 | Lonza Ltd | Process for the preparation of benzimidazoles |
CN102271514A (zh) * | 2008-10-30 | 2011-12-07 | 肿瘤疗法科学股份有限公司 | 7-羟基-苯并咪唑-4-基-甲酮衍生物以及包含其的pbk抑制剂 |
CN107434786A (zh) * | 2016-05-27 | 2017-12-05 | 广东东阳光药业有限公司 | 苯并咪唑化合物及其制备方法 |
-
2018
- 2018-12-12 CN CN201811514781.0A patent/CN109320461B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102271514A (zh) * | 2008-10-30 | 2011-12-07 | 肿瘤疗法科学股份有限公司 | 7-羟基-苯并咪唑-4-基-甲酮衍生物以及包含其的pbk抑制剂 |
WO2010149360A1 (en) * | 2009-06-26 | 2010-12-29 | Lonza Ltd | Process for the preparation of benzimidazoles |
CN107434786A (zh) * | 2016-05-27 | 2017-12-05 | 广东东阳光药业有限公司 | 苯并咪唑化合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
2-乙氧基-N-(4-甲基-2-丙基-1 H-咪唑基-1)-苯甲酰胺的合成;俞颖慧等;《合成化学》;20081231;第16卷(第5期);603-605 * |
Also Published As
Publication number | Publication date |
---|---|
CN109320461A (zh) | 2019-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109320461B (zh) | 一种替米沙坦中间体的制备方法 | |
CN101486669B (zh) | 一种合成牛磺酸的方法 | |
CN101671246B (zh) | 一种副产三水合乙酸钠和无水乙酸钠的方法 | |
CN114456059B (zh) | 一种制备阿福拉纳中间体的方法 | |
CN103772400A (zh) | 反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法 | |
CN104130262B (zh) | 一种厄他培南、厄他培南侧链及其制备方法 | |
CN101607892A (zh) | 枸橼酸钠的生产方法 | |
JP5192707B2 (ja) | ミルタザピンの製造方法 | |
CN108558679A (zh) | 一种Parylene A前驱体的合成方法 | |
CN108299149B (zh) | 高纯度oled中间体1-溴芘的合成法 | |
CN104355990B (zh) | 一种d-乙酯生产中回收和套用l-(+)-酒石酸的方法 | |
CN106336352A (zh) | 6‑氟水杨酸的一种合成方法 | |
CN101696185B (zh) | 6-硝基-s-(-)-吲哚啉-2-甲酸的合成方法 | |
CN108727297A (zh) | 一种橡胶促进剂二硫化二苯并噻唑的双氧水氧化一步合成工艺 | |
CN106674205A (zh) | 一种沙坦类化合物脱色的方法 | |
CN103664941B (zh) | 一种长春西汀类似物的制备方法 | |
CN109180493B (zh) | 由混硝基邻苯二甲酸制备3-硝基邻苯二甲酸与4-硝基邻苯二甲酸的方法 | |
KR101485418B1 (ko) | 고순도 미르타자핀의 제조방법 | |
CN112939941A (zh) | 一种兰索拉唑的制备方法 | |
CN112358489A (zh) | 一种青霉素亚砜工业化产品的生产方法 | |
CN104327011A (zh) | 一种医药级二硫化二苯并噻唑dm的生产工艺 | |
CN114044770B (zh) | 一种在水相中去除沙坦类化合物色素杂质的方法 | |
CN110668968A (zh) | 一种对氨基苯甲酰谷氨酸的制备方法 | |
CN112778196A (zh) | 一种维生素b6的制备方法 | |
CN108250148B (zh) | 一种替米沙坦关键中间体的精制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191226 Address after: 264205 Guangzhou East Road South and an East Road East, Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Applicant after: Dijia Pharmaceutical Group Co.,Ltd. Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 266440 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Applicant before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210609 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Patentee before: Dijia Pharmaceutical Group Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP02 | Change in the address of a patent holder |
Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP03 | Change of name, title or address |
Address after: No. 268, Tianrun Road, Wendeng Economic and Technological Development Zone, Weihai City, Shandong Province, 264200 Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of telmisartan intermediate Effective date of registration: 20230426 Granted publication date: 20200207 Pledgee: Weihai Branch of Shanghai Pudong Development Bank Co.,Ltd. Pledgor: Dijia Pharmaceutical Group Co.,Ltd. Registration number: Y2023980039205 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |